PriceTargets.com logo

CEL-SCI - CVM Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.56 As of 04/19/2024 01:00 AM ET
▲ +0.06 (4.00%)

This chart shows the closing price for CVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CEL-SCI Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for CEL-SCI in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.56.

This chart shows the closing price for CVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in CEL-SCI. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00N/A
2/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00N/A
12/29/2022EF Hutton Acquisition Co. ILower TargetBuy$17.00 ➝ $16.00N/A
5/14/2020HC WainwrightReiterated RatingBuy$18.00 ➝ $23.00N/A
1/13/2020HC WainwrightReiterated RatingBuy$18.00High
1/13/2020HC WainwrightInitiated CoverageBuy$18.00N/A
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CEL-SCI logo
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Read More

Today's Range

Now: $1.56
Low: $1.50
High: $1.57

50 Day Range

MA: $2.00
Low: $1.50
High: $2.46

52 Week Range

Now: $1.56
Low: $1.04
High: $3.23

Volume

227,075 shs

Average Volume

300,480 shs

Market Capitalization

$84.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of CEL-SCI?

The following Wall Street analysts have issued stock ratings on CEL-SCI in the last year: StockNews.com.
View the latest analyst ratings for CVM.

What is the current price target for CEL-SCI?

0 Wall Street analysts have set twelve-month price targets for CEL-SCI in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CEL-SCI in the next year.
View the latest price targets for CVM.

What is the current consensus analyst rating for CEL-SCI?

CEL-SCI currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CVM.

What other companies compete with CEL-SCI?

Other companies that are similar to CEL-SCI include AlloVir, Protalix BioTherapeutics, Curis, Entera Bio and Atara Biotherapeutics. Learn More about companies similar to CEL-SCI.

How do I contact CEL-SCI's investor relations team?

CEL-SCI's physical mailing address is 8229 Boone Boulevard, Suite 802, Vienna, VA 22182, United States. The company's listed phone number is 703-506-9460 and its investor relations email address is [email protected]. The official website for CEL-SCI is cel-sci.com. Learn More about contacing CEL-SCI investor relations.